In two phase 3 trials, lebrikizumab effective for primary outcome of IGA score of 0 or 1 and for achieving EASI-75<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, March 16, 2023 (HealthDay News) — For adults and adolescents with moderate-to-severe atopic dermatitis, 16 weeks of lebrikizumab is effective, according to a study published online March 15 in the New England Journal of Medicine<\/em>.<\/p>\n Jonathan I. Silverberg, M.D., Ph.D., M.P.H., from the George Washington University School of Medicine and Health Sciences in Washington, D.C., and colleagues conducted two identically designed, 52-week trials including a 16-week induction period and a 36-week maintenance period. Eligible patients were adults and adolescents with moderate-to-severe atopic dermatitis who were randomly assigned to receive lebrikizumab or placebo (283 and 141 patients, respectively, in trial 1; 281 and 146 patients, respectively, in trial 2), administered subcutaneously every two weeks.<\/p>\n The researchers found that in trial 1, the primary outcome of an Investigator’s Global Assessment score of 0 or 1, with a reduction of at least 2 points from baseline at week 16, was met by 43.1 and 12.7 percent of patients in the lebrikizumab and placebo groups, respectively, and a 75 percent improvement in the Eczema Area and Severity Index score (EASI-75 response) occurred in 58.8 and 16.2 percent, respectively. In trial 2, the primary outcome was met by 33.2 and 10.8 percent in the lebrikizumab and placebo groups, respectively; and an EASI-75 response occurred in 52.1 and 18.1 percent, respectively.<\/p>\n “Treatment with lebrikizumab led to significant improvements with regard to the signs and symptoms of moderate-to-severe atopic dermatitis in adults and adolescents,” the authors write.<\/p>\n The study was funded by Dermira, a wholly owned subsidiary of Eli Lilly, the manufacturer of lebrikizumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n